TScan Therapeutics, Inc.
TScan Therapeutics, Inc. (TCRX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
tcrx · stock forecast · 8 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$12.00
Consensus
$7.50
+654.6% upside
Low
$3.00
Median: $7.5 · Last Close: $0.99
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$7.50
654.6% upside
High Target
$12
1107.4%
Low Target
$3
201.8%
Current Price
$0.99
as of today
Based on analyst price targets, the TCRX stock price prediction for the next 12 months ranges from $3 to $12. The consensus TCRX price forecast of $7.50 implies 654.6% upside from the current price of $0.99.
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.96 | ↓ 3.16% |
1-day model range: $0.94–$0.98. Peak: $0.98 (-3.16%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -45.4% |
| 2028 | — | -57.8% |
| 2029 | — | -62.6% |
| 2030 | — | -64.7% |
| 2031 | — | -65.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · TCRX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-05 | Wedbush | Maintains | Outperform→Outperform |
| 2025-11-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-04 | Needham | Maintains | Buy→Buy |
| 2025-11-04 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2025-05-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-08 | Needham | Maintains | Buy→Buy |
| 2025-03-07 | Barclays | Maintains | Overweight→Overweight |
| 2025-03-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-05 | Needham | Maintains | Buy→Buy |
| 2024-12-11 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on TScan Therapeutics, Inc. (TCRX) stock. Of the recent 33 rating actions, 0 were upgrades and 1 were downgrades. 8 analysts currently cover TCRX.
Analyst Recommendation Trends
TCRX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$8M
↓ 71.2% YoY
Revenue Next Year
$8M
↑ 3.3% YoY
EPS This Year
$-1.05
EPS Next Year
$-0.97
↓ 8.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast TCRX EPS of $-1.05 for the current fiscal year, based on estimates from 4 analysts. The TCRX revenue forecast is $8M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The TCRX stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TCRX price target is $7.50 (+654.6% upside), with an analyst consensus of Buy.
The TCRX short-term stock prediction for tomorrow is $0.96 (-3.16%). The TCRX stock prediction for 2030 projects a range of $0–$0.
TScan Therapeutics, Inc. trades on NASDAQ under the ticker TCRX. The TCRX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 88% of covering analysts.
Frequently asked questions
TCRX forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month TCRX price target is $7.50, with a high forecast of $12.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies +654.6% potential upside from the current price of $0.99.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.